Seraseq® ctDNA EGFR Panel Reference Material AF0.1%

Driver mutations in the EGFR, BRAF, and KRAS genes represent a combined ~60% of all genomic variants driving oncogenesis of many solid tumor diseases, especially lung cancer. SeraCare is expanding its Seraseq liquid biopsy portfolio with the addition of low-plex (single-gene) reference materials for clinically-validated biomarkers as ground-truth standards for molecular testing of circulating tumor DNA patient samples by PCR or NGS technologies. These products are designed for validation and standardization of clinical biomarkers in CLIA/CAP-accredited laboratory developed tests (LDTs).

The Seraseq ctDNA EGFR Panel Reference Material AF0.1% product has an allele frequency of 0.1%.

• Size distribution similar to native cfDNA
• Offered in a full-process plasma-like material capable of assessing the entire workflow from extraction through analysis
• Mutation precisely quantitated with digital PCR
• Single well-characterized GM24385 human genomic DNA as background wild-type material
• Manufactured in GMP-compliant and ISO 13485-certified facilities